Article Text

Download PDFPDF
Application of pharmacovigilance tools in a case of subacute anterior angle narrowing while under furosemide exposure
  1. Emilie Anderssen-Nordahl1,
  2. Judit Riera-Arnau1,2,
  3. Manel Perelló Carrascosa3 and
  4. Alicia Gómez Muñoz4
  1. 1Department of Clinical Pharmacology, Vall d'Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalunya, Spain
  2. 2Immune Mediated Diseases and Innovative Therapies Research Group, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
  3. 3Department of Nephrology, Vall d'Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalunya, Spain
  4. 4Department of Glaucoma, Institut Català de la Retina (ICR), Barcelona, Spain
  1. Correspondence to Dr Judit Riera-Arnau;{at}


Sulfonamides have been related to drug-induced acute angle closure of the eye, but scarce reports exist concerning furosemide. We describe the second case of acute chamber narrowing (ACN) during furosemide exposure. A 65-year-old man with a renal transplant presented with ACN, after 3 months of furosemide intake. Finally, the patient required a bilateral iridotomy and right lens replacement. ACN has been associated with drugs containing sulfonamide derivatives, but an evaluation with pharmacovigilance scales for adverse drug reaction (ADR)-standardised causality assessment has not been provided. We use this case to illustrate how medicines and an ADR should be evaluated and reported. The spreading of pharmacovigilance information on what should be a rare and unexpected condition related to a drug could mean that other reports emerge about ADR with this drug and regulatory agencies perform consequently, as happened with topiramate.

  • eye
  • anterior chamber
  • unwanted effects / adverse reactions
  • safety
  • renal transplantation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @J_Riera_Farcli

  • Contributors EAN and JRA have written the article, established contact with the patient and created some of the figures/tables; MPC requested the revision of the patient’s condition relating to the drug, and together with AGM have fully revised the article. AGM has also provided images of the patient’s diagnosis procedures. The patient has provided relevant information about his case presentation, symptoms, diagnosis, follow-up and his perspective.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.